Publications by authors named "Michael Chirenje"
Article Synopsis
- Safer conception services are essential for HIV sero-discordant couples wanting to conceive, yet there is limited research on their experiences and preferences with various methods.
- A study involving 17 couples in Zimbabwe revealed that choices around safer conception were influenced by desires for intimacy and factors like method familiarity, ease of use, and effectiveness in preventing HIV while achieving pregnancy.
- Participants generally had positive experiences and satisfaction, particularly with ART/VL and PrEP, highlighting the importance of finding suitable methods for safe conception.
Article Synopsis
- Decision-making on childbearing for HIV sero-different couples requires balancing personal desires with perceived risks of HIV transmission, highlighting complex relationship dynamics.
- A study conducted interviews with 17 couples who participated in the SAFER study, exploring their experiences with safer conception methods and the importance of communication and gender roles in their decision-making.
- Findings suggest that safer conception programs need to focus on addressing power imbalances in relationships, enhancing couple communication skills, and providing support from healthcare providers to help couples make informed, safe reproductive choices.
Safer conception services are needed to minimize HIV transmission among HIV sero-different couples desiring pregnancy. Few studies have evaluated the choices couples make when offered multiple safer conception methods or real-world method acceptability and effectiveness. We piloted a comprehensive safer conception program (Clintrials.
View Article and Find Full Text PDFBackground: Invasive cervical carcinoma (ICC) accounts for 23% of all cancer-related deaths in Zimbabwean women. Trials for a national program of genotype-specific human papillomavirus (HPV) vaccines are underway to prevent cervical carcinoma, but the distribution of HPV types among women with ICC according to HIV status is unknown.
Methods: To determine prevalence and distribution of high-risk HPV genotypes by HIV status in women with ICC, we performed a cross-sectional study on women referred for ICC testing at 4 urban referral hospitals in Zimbabwe from June 2014 to December 2015.
Background: It is estimated that 1%-2% of women develop cervical intraepithelial neoplasia grade 2-3 (CIN 2-3) annually worldwide. The prevalence among women living with HIV is higher, at 10%. If left untreated, CIN 2-3 can progress to cervical cancer.
View Article and Find Full Text PDFIntroduction: In the Microbicide Trial Network MTN-003 (VOICE) study, a Phase IIB pre-exposure prophylaxis trial of daily oral or vaginal tenofovir (TFV), product adherence was poor based on pharmacokinetic (PK) drug detection in a random subsample. Here, we sought to compare behavioural and PK measures of adherence and examined correlates of adherence misreporting.
Methods: We included participants with PK and behavioural data from VOICE random subsample.
Objective. Cervical human papillomavirus (HPV) infection has been associated with human immunodeficiency virus (HIV) acquisition in populations with a high prevalence of both infections. Procedures performed in the management of cervical dysplasia may facilitate HIV entry via mechanical injury.
View Article and Find Full Text PDFBackground: Persistent infections with oncogenic human papillomavirus (HPV) types are causally related to cervical cancer. Little is known about the distribution of HPV types, independent risk factors of incidence and persistence, and patterns of persistence in sub-Saharan Africa.
Methods: A cohort of 2040 Zimbabwean women was enrolled in a randomized trial assessing the effect of diaphragm/gel provision on human immunodeficiency virus and HPV acquisition.
Objectives: To evaluate the safety of 100 mg nonoxynol-9 (N-9) gel, a vaginal microbicide, on the genital mucosa of women from Malawi and Zimbabwe in preparation for a phase III efficacy study.
Methods: HIV-uninfected women (180) were enrolled and randomized to either N-9 or placebo gel and instructed to insert gel into the vagina twice daily for 14 days. Follow up examinations were conducted at 7 and 14 days.
This paper provides the first comprehensive population based cancer survival estimates from the African continent. Five-year absolute and relative survival estimates are presented for black and white Zimbabwean patients diagnosed with cancer in Harare, Zimbabwe between the years 1993 and 1997. The survival of black Zimbabwean cancer patients are among the lowest ever reported from population based cancer registries.
View Article and Find Full Text PDFThe survival experience of 284 patients with cancer of the cervix uteri registered by the population-based Zimbabwe National Cancer Registry in 1995-1997 is described. The vital status of these subjects was established by linkage with death registration and by retrieval of patient files from medical records departments. Untraced patients were contacted at home.
View Article and Find Full Text PDF